NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

10939	Companies
238886	Keywords
167720	Articles
128405	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 10/31/2025 at 08:00, 10 months 7 days ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix announces $71M strategic royalty monetization agreement with Healthcare Royalty, extending cash runway and enabling long-term growth in cancer treatment

Cancer Treatment HealthCare Royalty Financial Agreement NANOBIOTIX Royalty Monetization
PRESS RELEASE

published on 10/31/2025 at 08:00, 10 months 7 days ago

NANOBIOTIX annonce un accord stratégique avec HealthCare Royalty pour un montant maximum de 71 millions de dollars et prolonge ainsi son horizon de trésorerie pour une croissance durable
Nanobiotix annonce un accord stratégique de 71 millions de dollars avec HealthCare Royalty pour étendre son horizon de trésorerie et soutenir la croissance à long terme

Croissance Financement Accord Stratégique HealthCare Royalty NANOBIOTIX
BRIEF

published on 10/01/2025 at 22:20, 11 months 5 days ago

NANOBIOTIX Reveals Promising Phase 1 Study Results for Esophageal Cancer Treatment

Phase 1 Study Radiotherapy Adverse Events JNJ-1900 (NBTXR3) Esophageal Cancer
BRIEF

published on 10/01/2025 at 22:20, 11 months 5 days ago

NANOBIOTIX révèle des résultats prometteurs d'une étude de phase 1 pour le traitement du cancer de l'œsophage

Étude De Phase 1 Radiothérapie JNJ-1900 (NBTXR3) Cancer De L'œsophage Événements Indésirables
PRESS RELEASE

published on 10/01/2025 at 22:15, 11 months 5 days ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Nanobiotix announces first data from Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with esophageal cancer. Results presented at ASTRO 2025 Annual Meeting

NANOBIOTIX Phase 1 Study JNJ-1900 Esophageal Cancer ASTRO
PRESS RELEASE

published on 10/01/2025 at 22:15, 11 months 5 days ago

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Nanobiotix annonce les premières données de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage. Taux de contrôle de la maladie de 85% et taux de réponse objective de 69%

NANOBIOTIX Phase 1 JNJ-1900 ASTRO Cancer De L’œsophage
PRESS RELEASE

published on 09/30/2025 at 22:27, 11 months 6 days ago

RAPPORT FINANCIER SEMESTRIEL
BRIEF

published on 09/30/2025 at 22:20, 11 months 6 days ago

Nanobiotix : Bilan financier et avancées cliniques au 1er semestre 2025

Résultats Financiers Biotechnologie NANOBIOTIX Johnson & Johnson JNJ-1900
BRIEF

published on 09/30/2025 at 22:20, 11 months 6 days ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 11 months 6 days ago

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025
Nanobiotix fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025, marqué par le développement clinique de JNJ-1900 et une gestion financière rigoureuse

Résultats Financiers Développement Clinique Gestion Financière NANOBIOTIX JNJ-1900

Accesswire

Published on 09/05/2026 at 04:05, 2 days 5 hours ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 2 days 9 hours ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 2 days 10 hours ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 2 days 10 hours ago

Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 2 days 18 hours ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/07/2026 at 09:00, 27 minutes ago

Original-Research: NanoRepro AG (von NuWays AG): BUY
Published on 09/07/2026 at 09:00, 27 minutes ago

Official List Notice
Published on 09/07/2026 at 08:59, 28 minutes ago

Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026
Published on 09/07/2026 at 08:30, 57 minutes ago

Restoration- Ferrexpo plc
Published on 09/07/2026 at 08:30, 57 minutes ago

Transaction in Own Shares

Les Echos

Published on 09/07/2026 at 08:30, 57 minutes ago

Dépôt d’une actualisation du document d’enregistrement universel
Published on 09/07/2026 at 08:25, 1 hour 2 minutes ago

Dépôt d’une actualisation du document d’enregistrement universel
Published on 09/07/2026 at 08:20, 1 hour 7 minutes ago

Derichebourg annonce le lancement d’une offre d’obligations vertes senior
Published on 09/04/2026 at 18:57, 2 days 14 hours ago

Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 18:57, 2 days 14 hours ago

Déclaration hebdomadaire d'opérations effectuées du 1er au 4 septembre 2026

View all LES ECHOS COMFI WIRE